Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542293 · ClinicalTrials.gov registry record · Phase 3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 953
- Enrollment target
- 20
- Study locations
NCT02542293 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 953 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT02542293, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 953 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
Conditions Studied
Interventions
- DRUG Gemcitabine + cisplatin
- DRUG Gemcitabine + carboplatin
- DRUG Paclitaxel + carboplatin
- DRUG Pemetrexed + cisplatin
- BIOLOGICAL Durvalumab +Tremelimumab
Study Locations (20)
Other
- Research Site - Berazategui
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - Córdoba
- Research Site - La Rioja
New York
- Research Site - East Setauket
- Research Site - Fresh Meadows
- Research Site - Poughkeepsie
- Research Site - Stony Brook
California
- Research Site - Anaheim
- Research Site - San Diego
- Research Site - Santa Rosa
Ohio
- Research Site - Canton
- Research Site - Columbus
- Research Site - Zanesville
Kentucky
- Research Site - Louisville
New Jersey
- Research Site - Florham Park
New Mexico
- Research Site - Albuquerque
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 953 participants |
| Start Date | 2015-11-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542293
The ClinicalTrials.gov registry entry for NCT02542293 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 953 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine + cisplatin is the first listed.
NCT02542293 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT02542293 about?
NCT02542293 is a clinical study titled "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lym...
What is the current status of trial NCT02542293?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 953 participants. The study started on 2015-11-03. Estimated completion is 2026-12-31.
What conditions does trial NCT02542293 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.
What interventions are being tested in trial NCT02542293?
The interventions under investigation include: Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Paclitaxel + carboplatin (DRUG), Pemetrexed + cisplatin (DRUG), Durvalumab +Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02542293?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02542293 being conducted?
This trial has 20 study locations across California, Kentucky, New Jersey, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.